Introduction to Targeted Protein Degradation in Virology

Researchers are increasingly exploring the nanobody-based bioPROTAC platform as a revolutionary tool for combating highly variable RNA viruses. Proteolysis-targeting chimeras (PROTACs) offer a distinct advantage over traditional inhibitors. Instead of merely blocking a protein's function, these molecules hijack the cell's natural disposal systems to destroy the target protein entirely. Consequently, this approach may overcome the drug resistance commonly seen in viruses with error-prone replication. This recent study establishes a modular platform derived from the speckle-type POZ protein (SPOP) to achieve rapid and precise antiviral drug construction.

Mechanism and Key Findings of the Study

The research team utilized the porcine reproductive and respiratory syndrome virus (PRRSV) as a model pathogen. They successfully fused nanobodies targeting the viral nonstructural protein 9 (Nsp9) to the BTB domain of SPOP. This fusion created functional bioPROTACs capable of specific protein degradation in a dose-dependent manner. Furthermore, employing a bivalent nanobody configuration significantly boosted degradation efficiency to over 60%. Specifically, the cytoplasmic version of the 9nb-SPOP chimera mediated Nsp9 degradation through the autophagy-lysosome pathway. This discovery is vital because it expands the use of SPOP-based degraders from nuclear proteins to those residing in the cytoplasm.

Broad Potential of the Nanobody-Based bioPROTAC Platform

The study also demonstrated the practical application of this technology through an mRNA-LNP delivery system. In piglet models, this combination suppressed viral proliferation and reduced mortality rates to 25%. Moreover, the treatment alleviated lung damage and decreased viremia levels within a short timeframe. Because the platform is modular, scientists can rapidly adapt it to different viruses by simply substituting the target-specific nanobody. Therefore, these findings provide a robust foundation for developing next-generation antivirals against multi-lineage pathogens and overcoming existing therapeutic barriers.

Frequently Asked Questions

How do bioPROTACs differ from traditional antiviral inhibitors?

Traditional inhibitors only block the active site of a protein, which viruses can bypass through mutations. In contrast, bioPROTACs cause the complete degradation of the target protein, offering a more sustained and comprehensive suppression of viral function.

What is the benefit of using an mRNA-LNP delivery system for these chimeras?

mRNA-LNP systems allow for the efficient in vivo delivery of genetic instructions that tell the host's own cells to produce the bioPROTAC. This method is rapid, scalable, and was proven effective in reducing viral load and clinical symptoms in animal models.

Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a substitute for professional healthcare. Refer to the latest local and national guidelines for clinical practice.

References

Su S et al. Nanobody-based bioPROTAC for viral protein degradation provides an antiviral strategy for porcine arterivirus. J Nanobiotechnology. 2026 Apr 05. doi: 10.1186/s12951-026-04348-8. PMID: 41935279.

Lim S, et al. PROTACs in Antiviral Therapy: Opportunities and Challenges. Front Cell Infect Microbiol. 2022;12:839556.

He M, et al. Nanobodies: A Promising Tool for Therapeutic Applications. Front Immunol. 2022;13:1015694.